SNS-032
SNS-032 works by interfering with the cancer cell's ability to relay information about replication and survival, resulting in the death of the cancer cell. At this time, SNS-032 is being studied in the B-lymphoid cancers such as chronic lymphocytic leukemia (CLL) and multiple myeloma.
Get general information about clinical studies, and learn about Sunesis investigational drugs currently in clinical trial.
Sunesis is an innovative biopharmaceutical company focused on therapeutics for oncology and other unmet medical needs.
Copyright © Sunesis Pharmaceuticals, Inc. 2007. All Rights Reserved.